DOI: 10.12890/2026_006059

Extracorporeal blood purification (HA-380) in rhabdomyolysis-induced acute kidney injury: a successful outcome

Authors

  • Marisa Cunha Intensive Care Unit, Unidade Local de Saúde de Santo António, Oporto, Portugal 0009-0006-5593-0522
  • Sílvia Sousa Intensive Care Unit, Unidade Local de Saúde de Santo António, Oporto, Portugal
  • Ricardo Marinho Intensive Care Unit, Unidade Local de Saúde de Santo António, Oporto, Portugal
  • Ana Castro Nephrology Department, Unidade Local de Saúde de Santo António, Oporto, Portugal
  • Aníbal Marinho Intensive Care Unit, Unidade Local de Saúde de Santo António, Oporto, Portugal

anamarisa_c@hotmail.com

Keywords

Rhabdomyolysis, acute kidney injury, renal replacement therapy, blood purification, haemoadsorption

Abstract

Background: Rhabdomyolysis (RM) is a multifactorial syndrome characterised by skeletal muscle breakdown and release of intracellular components, notably myoglobin, into the circulation. Elevated myoglobin levels are a major contributor to acute kidney injury (AKI), yet conventional renal replacement therapies (RRT) are limited in their ability to clear myoglobin due to its molecular size.
Case description: We present a case of a woman who developed severe RM-induced AKI secondary to necrotising myopathy. Despite initial fluid and diuretic therapy, her condition progressed to oliguric AKI. She was admitted to intensive care unit and prolonged intermittent RRT was then initiated. Due to markedly elevated myoglobin levels, a haemoadsorption device (HA-380 hemoperfusion cartridge) was added to the RRT circuit, leading to significant laboratory and clinical improvement.
Discussion: Severe RM frequently leads to AKI due to myoglobin-induced tubular damage. While conventional RRT removes myoglobin poorly, haemoadsorption using the HA-380 cartridge effectively reduced plasma myoglobin and creatine phosphokinase levels in our patient, supporting early implementation to enhance renal recovery. Evidence from case reports and recent studies suggests safety and efficacy, but clinical outcomes remain incompletely defined, and optimal therapy timing, thresholds and duration require further investigation.
Conclusion: This case highlights the potential utility of extracorporeal adsorption therapy as an adjunct to RRT for effective myoglobin removal in severe RM-induced AKI. Early implementation of this strategy may enhance renal recovery and improve outcomes, though clinical evidence remains limited.

View the entire article

Downloads

References

  1. Zimmerman JL, Shen MC. Rhabdomyolysis. Chest 2013;144:1058–1065. doi: 10.1378/chest.12-2016
  2. Chavez LO, Leon M, Einav S, Varon J. Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice. Crit Care 2016;20:135. doi: 10.1186/s13054-016-1314-5
  3. Kolovou G, Cokkinos P, Bilianou H, Kolovou V, Katsiki N, Mavrogeni S. Non-traumatic and non-drug-induced rhabdomyolysis. Arch Med Sci Atheroscler Dis 2019;4:e252–263. doi: 10.5114/amsad.2019.90152
  4. Petejova N, Martinek A. Acute kidney injury due to rhabdomyolysis and renal replacement therapy: a critical review. Crit Care 2014;18:224. doi: 10.1186/cc13897
  5. Hebert JF, Burfeind KG, Malinoski D, Hutchens MP. Molecular mechanisms of rhabdomyolysis-induced kidney Injury: from bench to bedside. Kidney Int Rep 2022;8:17–29. doi: 10.1016/j.ekir.2022.09.026
  6. Heyne N, Guthoff M, Krieger J, Haap M, Häring HU. High cut-off renal replacement therapy for removal of myoglobin in severe rhabdomyolysis and acute kidney injury: a case series. Nephron Clin Pract 2012;121:c159–164. doi: 10.1159/000343564
  7. Scharf C, Liebchen U, Paal M, Irlbeck M, Zoller M, Schroeder I. Blood purification with a cytokine adsorber for the elimination of myoglobin in critically ill patients with severe rhabdomyolysis. Crit Care 2021;25:41. doi: 101186/s13054-021-03468-x
  8. Dilken O, Ince C, van der Hoven B, Thijsse S, Ormskerk P, de Geus HRH. Successful reduction of creatine kinase and myoglobin levels in severe rhabdomyolysis using extracorporeal blood purification (CytoSorb®). Blood Purif 2020;49:743–747. doi: 10.1159/000505899
  9. Pomarè Montin D, Ankawi G, Lorenzi A, Neri M, Caprara C, Ronco C. Biocompatibility and cytotoxic evaluation of new sorbent cartridges for blood hemoperfusion. Blood Purif 2018;46:187–195. doi: 10.1159/000489921
  10. Moresco E, Rugg C, Ströhle M, Thoma M. Rapid reduction of substantially increased myoglobin and creatine kinase levels using a hemoadsorption device (CytoSorb®) – a case report. Clin Case Rep 2022;10:e05272. doi: 10.1002/ccr3.5272
  11. Gräfe C, Liebchen U, Greimel A, Maciuga N, Bruegel M, Irlbeck M, et al. The effect of CytoSorb® application on kidney recovery in critically ill patients with severe rhabdomyolysis: a propensity score matching analysis. Ren Fail 2023;45:2259231. doi: 10.1080/0886022X.2023.2259231
  12. Kousoulas L, Wittel U, Fichtner-Feigl S, Utzolino S. Hemoadsorption in a case of severe septic shock and necrotizing fasciitis caused by nontraumatic renal rupture due to pyelonephritis with obstructive uropathy. Case Rep Crit Care 2018;2018:5248901. doi: 10.1155/2018/5248901
  13. Forni L, Aucella F, Bottari G, Bütter S, Cantaluppi V, Fries D, et al. Hemoadsorption therapy for myoglobin removal in rhabdomyolysis: consensus of the hemoadsorption in rhabdomyolysis task force. BMC Nephrol 2024;25:247. doi: 10.1186/s12882-024-03679-8

Published

2026-01-08

Issue

Vol. 13 No. 1 (2026)

Categories

How to Cite

1.
Cunha M, Sousa S, Marinho R, Castro A, Marinho A. Extracorporeal blood purification (HA-380) in rhabdomyolysis-induced acute kidney injury: a successful outcome. EJCRIM [Internet]. 2026 Jan. 8 [cited 2026 Nov. 4];13(1). Available from: https://ejcrim.com/index.php/ejcrim/article/view/6059

Most read articles by the same author(s)